The main aim of the study is to assess if CNP-201 can reduce inflammation in participants with a peanut allergy who are on a peanut-free diet so that they can safely eat peanuts. All participants will receive CNP-201 or Placebo through the vein on Day 1 and Day 8.
Age 16-55 years old
Accepts healthy patients No, participants must have peanut allergy.
Active Clinical Sites
Allergy and Asthma Medical Group and Research Center